50.31
6.40%
-3.44
Dopo l'orario di chiusura:
50.31
Apogee Therapeutics Inc. Borsa (APGE) Ultime notizie
Apogee Therapeutics (NASDAQ:APGE) Trading Down 4% - Defense World
Defense World
SQZ Biotechnologies (NYSE:SQZ) & Apogee Therapeutics (NASDAQ:APGE) Head-To-Head Review - Defense World
Defense World
Apogee Therapeutics (NASDAQ:APGE) Shares Down 4% - MarketBeat
MarketBeat
New York State Common Retirement Fund Has $251000 Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Up 6.4% in April - MarketBeat
MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Update - Defense World
Defense World
Apogee Therapeutics Inc. (APGE) can make a big difference with a little luck – Sete News - SETE News
SETE News
Research Analysts Set Expectations for Apogee Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:APGE) - Defense World
Defense World
Apogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis Drug - TipRanks.com - TipRanks
TipRanks
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half ... - GlobeNewswire
GlobeNewswire
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
GlobeNewswire Inc.
Wedbush Comments on Apogee Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:APGE) - MarketBeat
MarketBeat
Wedbush Reiterates “Outperform” Rating for Apogee Therapeutics (NASDAQ:APGE) - Defense World
Defense World
Apogee Therapeutics (NASDAQ:APGE) Sees Large Volume Increase - MarketBeat
MarketBeat
Apogee Therapeutics, Inc. to Post Q1 2025 Earnings of ($0.63) Per Share, Wedbush Forecasts (NASDAQ:APGE) - MarketBeat
MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Stock Rating Reaffirmed by Wedbush - MarketBeat
MarketBeat
Stifel maintains buy on Apogee Therapeutics stock By Investing.com - Investing.com
Investing.com
Apogee Therapeutics selects APG-990 development candidate for atopic dermatitis - BioWorld Online
BioWorld Online
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results - ForexTV.com
ForexTV.com
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results - Yahoo Finance
Yahoo Finance
Apogee Therapeutics (NASDAQ:APGE) Research Coverage Started at Bank of America - Defense World
Defense World
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $52.92 - Defense World
Defense World
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $52.92 - MarketBeat
MarketBeat
B of A Securities Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - MSN
MSN
Bank of America Initiates Coverage on Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $52.92 - MarketBeat
MarketBeat
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter - InvestorPlace
InvestorPlace
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter - InvestorPlace
InvestorPlace
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - Marketscreener.com
Marketscreener.com
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - Yahoo Finance
Yahoo Finance
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - Yahoo Finance
Yahoo Finance
Apogee Therapeutics Insider Ups Holding During Year - Simply Wall St
Simply Wall St
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 6.1% - MarketBeat
MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Up 3.3% - MarketBeat
MarketBeat
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Zacks Investment Research
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why - Yahoo Finance
Yahoo Finance
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
GlobeNewswire Inc.
Apogee Therapeutics Launches Innovative Antibody Clinical Trial - TipRanks.com - TipRanks
TipRanks
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Benzinga
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
GlobeNewswire Inc.
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option ... - GlobeNewswire
GlobeNewswire
Public equity report: Boundless to test IPO appetite as follow-ons continue to deliver - BioCentury
BioCentury
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
GlobeNewswire Inc.
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering - GlobeNewswire
GlobeNewswire
Clinical report: Akero's efruxifermin shows deepening treatment effect at 96 weeks - BioCentury
BioCentury
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
GlobeNewswire Inc.
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
Benzinga
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Nasdaq Down 250 Points; ISM Services PMI Falls In February
Benzinga
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
Benzinga
Capitalizzazione:
|
Volume (24 ore):